ERBB2 and neoplasm: Whereas injection of liposomal carrier had no effect on tumour growth, and all animals in this group had to be killed due to the size of their tumours latest until day 43 of the experiment (Figure 5B), two out of five mice treated by therapeutic vaccination with mono-epitope Tc-ErbB2 liposomes and three out of five mice treated with diepitope Tc-ErbB2/Th-HA liposomes had completely rejected the established tumours by day 20 and remained tumour free until day 86 when the experiment was terminated.